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1. Introduction 
The focus of this chapter is drug-eluting stents (DES) for the treatment of coronary artery 
disease (CAD). The clinical trial programs for the main DES approved by the Food and Drug 
Administration (FDA) for the treatment of CAD are presented. CAD is the leading cause of 
death in both men and women around the world. In the United States alone, there is a 
coronary event that occurs every 25 seconds and someone will die from a coronary event 
every minute (Roger et al., 2011). The current treatment options for ischemic CAD include 
medications, percutaneous interventions, and surgery to perform coronary artery bypass 
grafting (CABG). According to the American Heart Association (AHA) 2011 Statistics 
Update, the total number of percutaneous coronary interventions (PCI) procedures 
performed in 2007 was 1,178,000 compared to 408,000 CABG operations. With risk factors 
like obesity and diabetes prevalence increasing globally, the number of CAD interventions 
will likely continue to rise in the future and require more specialized treatment options for 
more complex lesions and patient populations.  
In past decades, percutaneous angioplasty (PTCA) or plain old balloon angioplasty (POBA) 
was used to treat obstructive coronary lesions but had frequent incidence of abrupt closure 
and restenosis. The use of bare metal stents (BMS) helped to address the limitations of 
PTCA, as evident by reduced angiographic restenosis and target vessel revascularizations 
(TVR) in earlier clinical trials. The results of these trials led to the first FDA approved 
balloon-expandable BMS, the Palmaz-Schatz stent (Cordis Corp; a Johnson and Johnson 
Company) and the Gianturco-Roubin coil stent (Cook Inc, Bloomington, IN) (Fischman et 
al., 1994; Serruys et al., 1994). Compared to PTCA, the development of BMS reduced the 
need for urgent CABG associated with abrupt closures and restenosis, but the need for 
repeat procedures persisted (Doostzadeh et al., 2010). Although BMS provided the 
structural support to prevent abrupt closures, arterial wall recoil, and negative arterial wall 
remodeling, the problem of neointimal hyperplasia was not remedied by BMS. Some of the 
earlier trials evaluating BMS demonstrated that restenosis occurred in about 20% of cases by 
6 months (Doostzadeh et al., 2009). The development of DES emerged and intended to 
deliver localized pharmaceutical agents targeted to reduce restenosis.  
In order for DES to optimize therapeutic benefits with minimal risks, several factors must be 
considered. The stent cell design, strut thickness, polymer technology, mechanism of drug, 
www.intechopen.com
 
Coronary Interventions 
 
156 
and pharmacokinetics must all be considered to minimize vessel injury and prevent delayed 
healing while allowing appropriate endothelialization and avoiding loss of coating integrity, 
especially during stent delivery and expansion. In order to evaluate the safety and efficacy 
of DES, the early trials were designed with a BMS comparator arm and used similar 
endpoints as the previous BMS trials. DES were originally compared to BMS in the RAVEL,  
TAXUS I, ENDEAVOR I, and SPIRIT FIRST first-in-man clinical trials. These early clinical 
trials favored the DES arms with reduction in restenosis, major adverse cardiac events 
(MACE), and revascularizations compared to BMS (Grube et al., 2003; Morice et al., 2002; 
Moses et al., 2003; Serruys et al., 2002a). DES appeared to address the needs for safe and 
efficacious PCI for ischemic coronary arterial disease. The underlying metal stent of a DES 
system provided the structural support to reduce abrupt closure and recoil, while covering 
the outside of the stent with a platform to deliver pharmaceutical agents that reduced 
neointimal hyperplasia. As a result, DES replaced BMS as the predominant PCI therapy for 
suitable patients over the past decade. To date, there are four main commercially available 
DES manufacturers in the U.S. that will be highlighted in this chapter; Cordis-Johnson and 
Johnson, Boston Scientific, Medtronic, and Abbott Vascular. Although improved clinical 
outcomes with these DES have been evident, the risk of stent thrombosis (ST) was 
previously believed to be one of the potential draw backs of DES compared to BMS. The 
FDA Circulatory Advisory Panel released a statement following an extensive panel review 
of trial results and noted that there was no subsequent increase in deaths or MIs from ST in 
patients treated with DES per the on-label, approved indication (FDA, 2006). The use of dual 
antiplatelet therapy (DAPT) has been recommended up to 12 months following the 
procedure in patients that are not at high risk for bleeding per the ACCF/AHA/SCAI 2007 
guidelines (King, 2007). The ideal duration of DAPT continues to be explored as DES is now 
utilized in more high risk patients and in real-world settings. The current improvements for 
DES focus on drug delivery platforms and bioresorbable stents that may remove potential 
contributing factors of the stent that cause stent thrombosis. Therefore, this chapter will 
conclude with an overview of new stent technology currently being evaluated in clinical 
trials. 
2. CYPHER
®
 and NEVO™ 
The first DES to be approved in the U.S by the FDA in 2003 was CYPHER, manufactured by 
Cordis Corp; a Johnson and Johnson Company. The CYPHER stent is the Bx Velocity bare 
metal stent comprised of 316L stainless steel and has three non-eroding polymer coatings 
with the active drug, sirolimus loaded throughout the coating, but outside of the stent. The 
basecoat of the stent contains a combination of two non-erodible polymers; n-butyl 
methylacrylate (PBMA) and polyethylene co-vinyl acetate (PEVA). The two polymers are 
mixed in a combination with the sirolimus and applied to a parylene C treated stent, which 
is covered lastly by a drug-free polymer coating of PBMA (accessed online at 
http://www.cordislabeling.com). The polymer coating thickness is 13.7 µm and as an early 
stent design, the strut thickness is subsequently one of thickest (140 µm). The CYPHER stent 
sizes available range from 8 mm – 33 mm long and diameter sizes of 2.25 mm – 3.50 mm 
with a maximum sirolimus dose of 314 µg. Sirolimus (rapamycin) has lipophilic properties 
that favor the diffusion across cell membranes of the smooth muscle cells. It is not well 
understood, but thought that once in the cell, sirolimus binds to the FKBP12 cytoplasmic 
intracellular protein, which subsequently inhibits the mammalian target of rapamycin 
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(mTOR) regulatory enzyme. The inhibition of mTOR interrupts the cell cycle at the G1 phase 
and will subsequently inhibit proliferation of smooth muscle cells (Sousa et al., 2001).  
The CYPHER stent was approved for commercialization in the U.S. based on the results 
from the RAVEL and SIRIUS trials. The CYPHER stent received a clinical indication to 
improve coronary artery lumen diameter in patients with ischemic de novo coronary lesions 
measuring ≤ 30 mm long in native coronary arteries measuring ≥ 2.25 mm and ≤ 3.5 mm in 
diameter (accessed online at http://www.cordislabeling.com). The RAVEL study was a 
randomized, multicenter, double-blind trial that evaluated the CYPHER sirolimus-eluting 
stent system (SES) compared to the Bx Velocity BMS in single de novo coronary lesion 
treatable by a single 18 mm length stent. The trial enrolled 120 patients in the CYPHER arm 
and 118 patients in the control (BMS) arm. As reported by Morice et al. and Serruys et al. 
(2002) (Morice et al., 2002; Serruys et al., 2002b), the primary endpoint of in-stent late loss 
(LL) favored the CYPHER arm and the angiographic binary restenosis (ABR) rate was 0% in 
the CYPHER arm compared to 26.6% in the BMS arm at 6 months. The CYPHER arm also 
favored in clinical endpoint results, as no events of target lesion revascularization (TLR)  or 
target vessel revascularization (TVR) occurred at one year, compared to the BMS arm rates 
of 23.7% and 26.0%, respectively (Morice et al., 2002; Serruys et al., 2002b). With the 
promising results demonstrated in the RAVEL trial, the CYPHER stent was evaluated in 
longer lesions between 15 and 33 mm in length in the SIRIUS trial. There were 533 patients 
enrolled in the CYPHER arm and 525 patients in the Bx Velocity arm. The SIRIUS trial was a 
randomized 1:1 multicenter trial and was the pivotal trial that led to FDA approval in the 
U.S. Compared to the RAVEL trial, the SIRIUS trial enrolled patients with more complex 
characteristics, such as diabetes, overlapping stent usage, and longer lesions. The mean 
lesion length in the CYPHER sirolimus-eluting stent system (SES) arm in the RAVEL trial 
was 9.56 mm compared to 14.4 mm in the SIRIUS trial (Htay and Liu, 2005). The primary 
endpoint was target vessel failure (TVF; defined as target vessel revascularization, cardiac 
death or Q-wave and non-Q-wave MI not clearly attributed to a vessel other than the target 
vessel) and showed statistical significance in favor of the SES arm compared to the Bx 
Velocity BMS arm, respectively (8.8% versus 21.0%, p < 0.001) and also demonstrated 
significant reductions in TLR rates for the SES arm compared to the BMS arm at 1 year, 
respectively (4.1% versus 16.6%, p < 0.001) (Holmes, 2003).  
Trials conducted in Europe and Canada that evaluated CYPHER compared to the Bx 
Velocity, the E-SIRIUS and C-SIRIUS trials showed consistent results that favored the SES 
arms compared to the BMS arms. The TLR rates remained numerically lower in the SES arm 
(4.0%) compared to the BMS arm (20.9%) in the E-SIRIUS trial and also the C-SIRIUS trial 
(4.0% versus 18.0%, respectively) (Schampaert et al., 2004; Schofer et al., 2003). Following 
FDA approval in 2003, post-marketing surveillance was initiated in the CYPHER Stent Post-
Market Registry in 2003 and the e-SELECT post-market Registry in 2006. The post-market 
trials were designed as open-label, single-arm, multicenter trials that enrolled real-world 
treated patients. The CYPHER Stent Post-market registry enrolled up to 15,000 patients and 
the e-SELECT trial enrolled up to 2070 patients to continue monitoring safety and 
surveillance required by the FDA. Since the initial approval, multiple registries out of the 
U.S (OUS) have been initiated as well, such as in Israel, China, and India. The SIRIUS 2.25 
mm pivotal trial was conducted to evaluate the safety and efficacy of the SES 2.25mm stent 
for the reduction of angiographic binary restenosis at 6 months in patients with reference 
vessel diameters between 2.0 and 2.5 mm and lesion lengths ≤ 20 mm. The trial was a non-
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randomized, multicenter, prospective trial that compared propensity scores matched results 
from plain old balloon angioplasty (POBA), Palmaz Schatz, and Bx VELOCITY to the SES 
2.25mm treated patients. The outcomes were favorable for the SES 2.25 mm stent arm and 
were consistent with previous CYPHER trials. Table 1 below highlights the first-in-man 
(FIM), pivotal, and post-marketing trials conducted for the CYPHER DES. 
 
Trial Design 
Sample 
size 
Primary 
endpoint 
SES 
treatment 
arm 
BMS 
treatment 
arm 
P value 
RAVEL 
Randomized, 
multi-center 
238 
In-stent late 
loss at 6 
months 
0.01±0.33 
mm 
0.80±0.53 
mm 
P < 0.001 
SIRIUS 
Randomized 
multicenter 
1,058 
Target 
vessel 
failure 
(TVF)* at 9 
months 
8.6% 21.0% P < 0.001 
CYPHER Post-
Marketing 
Surveillance 
Registry (2003) 
Open label, 
single arm, 
multicenter 
2067 
Major 
adverse 
cardiac 
event 
(MACE)▲ 
and TLR at 
1 year 
MACE 
7.3% 
TLR 4.6%
Not 
applicable 
(NA) 
Not 
applicable 
(NA) 
e-SELECT 
Registry (2006) 
Open label, 
single arm, 
multicenter 
15,000 
Composite 
of stent 
thrombosis 
(ST) per 
ARC-
definite/ 
probable  at 
3 years 
1.0% (1 yr)
(3 yr data 
not 
available 
to date) 
Not 
applicable 
(NA) 
Not 
applicable 
(NA) 
*TVF = target vessel revascularization, cardiac death, or Q-wave and non-Q-wave MI not clearly 
attributed to a vessel other than the target vessel. ▲MACE = death, Q-wave and non-Q-wave MI, and 
emergent coronary artery bypass graft (CABG), target lesion revascularization (TLR).  
Table 1. Clinical trials evaluating the CYPHER SES 
One of the challenges faced with these earlier pivotal trials (SIRIUS and RAVEL) was the 
small sample sizes that were underpowered to discern differences in stent thrombosis (ST) 
rates between the DES and the BMS arms (Morice et al., 2007; Weisz et al., 2006). As 
registries collected data on larger populations, a potential increased safety risk of stent 
thrombosis was questioned with DES use compared to BMS (Lagerqvist et al., 2007; Moreno 
et al., 2005). During the 2006 FDA Circulatory Advisory Panel, it was concluded that 
expanded use of DES beyond the approved indication in more complex patients may 
contribute to the incidence of ST in DES (FDA, 2006). The antiplatelet medication 
recommendations were also modified to extend clopidogrel usage for up to 12 months for 
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those patients treated with DES that are not at high risk for bleeding in order to potentially 
reduce ST events (King et al., 2007). As more long term data has become available over the 
past decade, the concern for increased ST in DES has diminished while strategic new stent 
technology has been evolving into next generation stent designs. 
The next generation of DES under development by Cordis is the NEVO™ sirolimus-eluting 
stent system (NEVO SES) that has a cobalt chromium alloy platform with reservoirs loaded 
with a bioabsorbable polymer, polyglycolic lactic acid (PGLA), combined with sirolimus. 
The strut thickness (100 µm) is thinner than the original CYPHER SES platform and there is 
an open-cell design that may aid in conformability and flexibility. One of the potential 
benefits of the reservoir technique for localized drug delivery on a stent, is that the surface 
area of polymer exposure to the vessel is reduced, which may help to reduce sensitivity or 
inflammatory responses to polymer that result in events. Furthermore, the NEVO SES elutes 
sirolimus within 90 days from implant while the PGLA degrades, leaving only a bare metal 
scaffold in place which may help reduce ST attributed to permanent polymer coatings 
(Otake et al., 2011a).  
The NEVO ResElution-1 trial was a randomized, multicenter, prospective trial that was 
designed to demonstrate the non-inferiority of NEVO SES compared to a second generation 
paclitaxel-eluting stent (PES), the TAXUS® Liberté® PES (see 3.0 below) in terms of in-stent 
late loss at 6 months. The trial enrolled 394 patients and met the primary endpoint; NEVO 
SES was non-inferior to TAXUS Liberté for in-stent late loss, respectively (0.13 ± 0.31 and 
0.36± 48, p <0.001) and demonstrated more uniform suppression of neointimal hyperplasia 
(Spaulding, 2011). Numerically lower rates of MACE, death, MI, and revascularization have 
also been demonstrated in favor of the NEVO SES arm compared to the TAXUS Liberté arm 
through 24 months, as well as no events of ST in the NEVO SES arm (Spaulding, 2011). The 
NEVO ResElution-1 IVUS sub-study was also conducted and enrolled 100 patients and had 
3D intravascular ultrasound (IVUS) studies available on 64 patients at 6 months, which 
showed that a significant reduction in neointimal obstruction occurred in the NEVO SES 
arm (5.5 ± 11.0%) compared to the TAXUS Liberté arm (11.5 ± 9.7%), p = 0.02 (Otake et al., 
2011a). There was no event of ST in the NEVO SES arm at 6 months compared to 1 event in 
the TAXUS Liberte ́ arm, and clinical outcomes were overall comparable for death, MI, and 
TLR (Otake et al., 2011a). Long-term follow-up will continue in the NEVO-SES trial 
through 5 years. On June 15th, 2011 however, it was announced that CYPHER and NEVO 
clinical trial programs would be ending due to production cost and declining market 
share, thus ending future CYPHER-biodegradable new stent technologies for the 
treatment of CAD. 
3. TAXUS
®
 and PLATINUM™  
The TAXUS Express2™ paclitaxel eluting stent system (PES) was initially approved by the 
FDA in 2004, becoming the second DES to be commercially available in the U.S. The TAXUS 
Express2 PES utilizes paclitaxel as the active drug agent, which is a plant based alkaloid that 
disrupts the cellular microtubules by binding to tubulin and subsequently arrests the cell 
cycle at the M phase (Rowinsky and Donehower, 1995). The earliest TAXUS DES implanted 
in humans was the NIR™ stainless steel closed cell design. The uncoated NIR BMS was used 
as the scaffold in the TAXUS I, II, and III trials and it is coated with a paclitaxel dose of 1 
µg/mm2 (Halkin and Stone, 2004). The biphasic polymer-controlled drug release of this stent 
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design elutes paclitaxel in two phases; an initial  burst release  phase within the first 48 
hours followed by a slower  release   phase over the next 10 days (Halkin and Stone, 2004). 
The TAXUS Express1 and TAXUS Express2 were later utilized in the pivotal trials (TAXUS 
IV and TAXUS V) and also had a stainless steel platform with tandem cell architecture and 
strut thickness of 132 µm and a non-degradable TRANSLUTE™ polymer-coating containing 
paclitaxel. The TRANSLUTE polymer coating thickness is approximately 16 µm and consists 
of polylactide-co-caprolactone, which provides a uniform and controlled release of 
paclitaxel with a drug density of 1 µg/mm2 (Hellige and Windecker, 2009). There are three 
profiles that were developed and the paclitaxel to polymer ratios for fast, moderate, and 
slow release profiles are 35:65, 25:75, and 8.8:91.2, respectively, with varying degrees of drug 
release over time (Acharya and Park, 2006). The long-term retention of paclitaxel within the 
stent has raised concerns over delayed healing or hypersensitivities that may contribute to 
the development of very late stent thrombosis (Joner et al., 2006). 
The first-in-man trial evaluating a PES was the TAXUS I trial that compared TAXUS NIR 
PES to the bare-metal stent (BMS) counterpart. TAXUS I was designed as a multicenter RCT 
that enrolled approximately 61 patients and had a primary endpoint of major adverse 
cardiac events (MACE) at 30 days follow-up. Patients were randomized 1:1 to receive a 
single 12 mm long TAXUS-SR PES or BMS in de novo coronary vessels measuring 3.0-3.5 
mm diameter (Halkin and Stone, 2004). Although the study was designed primarily to 
evaluate safety, the low late loss and neointimal hyperplasia in the TAXUS arm suggested 
benefits of this DES when compared to the BMS counterpart similarly observed in the 
RAVEL and SIRIUS trials. At 30 days, there was no difference observed in MACE rates, as 
both the TAXUS and the BMS arms had no events and numerically low rates persisted at 
one year in favor of the TAXUS NIR arm respectively, 3.0% versus 10.0% (Colombo et al., 
2003; Grube et al., 2003). At six months, the in-stent LL in the TAXUS NIR arm was 0.36 ± 48 
mm compared to 0.71 ± 0.47 mm in the BMS arm (p value = 0.008) and the neointimal 
hyperplasia volume was 14.8 ± 10.8 compared to 21.6 ± 10.7 mm3 (p value = 0.028), 
respectively (Halkin and Stone, 2004). The TAXUS II trial was also designed as a 
multicenter RCT but expanded enrollment to approximately 536 patients that were 
randomized to either TAXUS SR (n = 131), TAXUS MR (135), or the NIR BMS (n = 134) 
counterpart. The primary endpoint was % in-stent volume obstruction at 6 months and 
was statistically significant in favor of the TAXUS SR and TAXUS MR patients compared 
to the BMS treated patients (p < 0.001) (Colombo et al., 2003). The in-stent LL and TLR 
rates continued to favor the TAXUS SR and MR treated patients through long-term 
follow-up as well with no late thrombosis events occurring between two and three year 
follow-up in the DES treated patients.  
The feasibility to treat patients with in-stent restenosis was explored in TAXUS III which 
was designed as an uncontrolled, single-arm, multicenter pilot study. The trial enrolled 28 
patients treated with TAXUS PES for in-stent restenosis following previous BMS treatment 
and was further explored in the TAXUS V-ISR trial, which enrolled 396 patients and 
compared TAXUS PES (195 patients) to balloon angioplasty followed by vascular 
brachytherapy (201 patients) (Stone et al., 2006; Tanabe et al., 2003). The results supported 
the safety and efficacy of TAXUS PES compared to vascular brachytherapy, with 
numerically lower rates of stent thrombosis, MACE, MI, and TLRs compared to the BMS 
arm (Lasala et al., 2006).  
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TAXUS IV was designed as randomized, controlled, multicenter trial that enrolled 
approximately 1,314 patients in the U.S for the treatment of single vessel disease with de 
novo coronary lesions. The primary endpoint was TVR at 9 months and compared the 
TAXUS Express PES to BMS in patients with reference vessel diameter (RVD) of 2.5 -3.75 
mm and de novo lesions measuring 10-28 mm in length to be coverable by a single stent 
(Halkin and Stone, 2004). The baseline characteristics were notably well matched between 
the DES and the BMS arm, as the mean RVD and lesion lengths were the same in both 
arms, respectively 2.75 mm and 13.4 mm. At 9 months, statistically significant differences 
were noted between the TAXUS DES and BMS in the primary endpoint, as well as for 
MACE and TLR. The primary endpoint results for TVR at 9 months was 8.5% in the 
TAXUS DES arm compared to 15.0% in the BMS arm (p = 0.0002), as well as showing 
significance in TLR at 9 months (Halkin and Stone, 2004). The TLR rates were statistically 
significant at 9 months in favor of the TAXUS DES arm in patients with orally medicated 
treated diabetes (p < 0.0001) and non-diabetes (p < 0.0001), with the exception of patients 
with insulin treated diabetes (p = 0.32) (Halkin and Stone, 2004). For the safety endpoints 
of death, MI, and stent thrombosis (ST) were non-significant at 9 months in the overall 
population and suggested that clinical safety was not compromised in exchange for more 
efficacy with the use of DES.  
To further evaluate the TAXUS Express PES in more complex patient populations, the 
TAXUS V and TAXUS VI clinical trials aimed to evaluate results when compared to BMS. 
The TAXUS V clinical trial was a randomized, multicenter trial that enrolled 1156 patients 
with de novo lesions measuring 10-46 mm in length in reference vessel diameters between 
2.25 – 4.0 mm; a minimum of 200 patients each with a 2.25 mm diameter or a 4.0 mm 
diameter were enrolled, as well as a minimum of 300 patients with overlapping stents 
(Halkin and Stone, 2004). The rates of the primary endpoint of TVR at 9 months were higher 
in the DES arm than previously observed in the earlier trials, yet still demonstrated a 
statistically significant difference compared to the BMS arm at 9 months (p = 0.0184) 
(Stone et al., 2005). TAXUS VI trial was designed to evaluate the performance of TAXUS 
Express compared to BMS and was a multicenter, randomized controlled trial with a 
primary endpoint of TVR at 9 months and enrolled 446 patients. The results of the 
primary endpoint revealed that TAXUS Express TVR rates at 9 months were numerically 
lower than the TAXUS Express rates from the TAXUS V trial, but both continued to 
outperform the BMS counterpart in reducing revascularization events (Dawkins et al., 
2005). Following approval of the TAXUS Express, the ARRIVE I and II post-market 
surveillance registries were initiated to continue to monitor safety in ‘real-world’ setting 
patients that receive treatment with the TAXUS Express. Patients enrolled in the post-
market registries or all-comer trials may not have been eligible in the previous RCTs that 
have specific inclusion and exclusion criteria, and thus may give a broader perspective of 
how the stent performs in real clinical practice with more complex patient and lesion 
subsets. The ARRIVE-1 was the first post-market registry for TAXUS and enrolled over 
2000 patients and the ARRIVE-II registry enrolled over 4,000 patients (Dobies, 2007; 
Lasala et al., 2006). Boston Scientific pooled the data from these registries and was able to 
show that TAXUS was used in patient populations more complex than previously 
evaluated in the RCTs, such as bifurcation lesions, acute myocardial infarction, and ostial 
lesions (Lasala et al., 2006). 
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Trial Design 
Sample 
size 
Primary 
endpoint 
PES 
treatment 
arm 
BMS 
treatment 
arm 
P value 
TAXUS I 
 
Randomized 
multicenter 61 
MACE at 30 
days 
0.0% 0.0% 
Not 
significant 
(under 
powered) 
TAXUS II 
 
Randomized, 
multicenter 536 
% in-stent 
volume 
obstruction 
at 6 months
SR 7.9% 
MR 7.8% 
23.2% 
20.5% 
P < 0.001 
P < 0.001 
TAXUS IV 
 
Randomized 
multicenter 1,314 
TVR at 9 
months 
4.7% 11.3% P < 0.001 
TAXUS V 
 
Randomized 
multicenter 1,156 
TVR at 9 
months 
12.1% 17.3% P = 0.0184 
TAXUS VI 
 
Randomized, 
multicenter 446 
TVR at 9 
months 
9.1% 19.4% P = 0.0027 
ARRIVE I & 
II 
Pooled post-
marketing 
surveillance 
Open label, 
single arm, 
multicenter 
7,492 
TAXUS 
stent 
related 
cardiac 
events at 1 
year 
9.5% 
Not 
applicable
Not 
applicable 
Table 2. Clinical trials evaluating TAXUS paclitaxel-eluting stents 
The next generation of TAXUS stent was the TAXUS Liberté PES evaluated in the ATLAS 
program and was conducted similarly to the TAXUS Express program, with an ATLAS de 
novo, ATLAS expansion, and OLYMPIA registry. These trials evaluated unmet needs in 
DES and aimed to expand the indications for use in these more complex lesion and patients. 
The TAXUS Liberté stent was approved for commercialization in the U.S by the FDA on 
April 12, 2005 and uses the same open-cell design, Translute polymer, and paclitaxel drug as 
the TAXUS Express system yet has thinner polymer (17 µm) and thinner struts (97 µm). The 
ATLAS trial was a single-arm, multicenter trial that used a historical control group with 
matched lesions from the TAXUS IV and V clinical trials. The primary endpoint was non-
inferiority compared to the historic control group in terms of TVR at 9 months. The TAXUS 
Liberté stent demonstrated non-inferiority compared to the historic control, despite having 
more complex patients evaluated in the TAXUS Liberté arm (Turco, 2008). The ATLAS 
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program expanded to evaluate small vessel and long lesion treatment with the TAXUS 
Liberté stent in the ATLAS Small Vessel 2.25 mm and ATLAS Long Lesion clinical trials 
(Table 3).  
 
Trial Design 
Sample 
size 
Primary 
endpoint 
PES 
treatment 
arm 
Comparator 
arm 
P value 
TAXUS 
ATLAS 
(TAXUS 
Liberté) 
Single arm 
compared to 
historical 
TAXUS IV and 
V PES control 
group, 
multicenter 
 
871 
TVR at 9 
months 
7.95% 7.01% 
P non-
inferiority = 
0.0487 
TAXUS 
Liberté 
ATOM -
ATLAS 
Small Vessel 
(Expansion) 
Single arm 
compared to 
DES and BMS, 
multicenter 
261 
% 
Diameter 
stenosis at 
9 months 
32.2% 
PES 39.6% 
BMS 40.1% 
p < 0.0001 
TAXUS 
ATLAS Long 
Lesion 
Single arm 
compared to 
historical 
TAXUS IV and 
V PES control 
group, 
multicenter 
150 
% 
Diameter 
stenosis at 
9 months 
31.4% 35.5% p < 0.0001 
ION –
PERSEUS 
 
Randomized, 
multicenter 
compared to 
TAXUS 
Express 
1264 
TLF at 12 
months 
5.6% 6.1% p = 0.003 
ION – 
Small Vessel 
 
Open label, 
single arm, 
compared to 
BMS 
224 
In-stent 
late loss at 
9 months 
0.38 ± 0.51 0.80 ± 0.53 p < 0.0001 
Accessed at http://www.bostonscientific.com/templatedata/imports/collateral/eDFU/ 
Table 3. Clinical trials evaluating TAXUS Liberté and ION Element stents 
The most recent generation of DES developed by Boston Scientific, the Platinum Element 
ION PES (ION), has additional design changes from the TAXUS Liberté that aim to further 
improve patient outcomes. Studies have suggested that various alloys provide different 
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strength and allow for thinner struts that subsequently enhance healing and may reduce 
revascularizations (Ako et al., 2007; Joner et al., 2008; Kastrati et al., 2001). The Platinum ION 
PES system was approved by the FDA on April 22, 2011 as the latest generation of DES and 
utilizes a platinum chromium alloy stent but uses the same polymer and drug as the TAXUS 
Express with the same concentration (1 µg/mm2). The improved design offers thinner struts 
(81 µm) and thin polymer layer (14.9 µm). The ION stent system has been evaluated in the 
PERSEUS clinical trial for the treatment of de novo coronary lesions of ≤ 28 mm length in 
vessels measuring between 2.75 – 4.0 mm. The PERSEUS clinical trial is a randomized 
controlled trial comparing the ION stent system to the TAXUS Express stent and has a 
primary endpoint of target lesion failure (TLF) at 12 months. The primary endpoint was met 
and the ION stent demonstrated non-inferiority compared to the well established TAXUS 
Express stent in terms of TLF at 12 months. The ION stent has also been evaluated in vessel 
sizes ≥ 2.25 and < 2.75 mm diameter and lesion lengths ≤ 20 mm in the ION Small Vessel 
trial versus the performance of BMS from TAXUS IV and V historical comparator arms 
(Table 3). The primary endpoint was in-stent late loss at 9 months and superiority (p < 
0.0001) was met compared to the BMS control arm and furthermore, ION has also 
demonstrated comparable results to the TAXUS Liberté stent (Meredith, 2011). From the 
first generation TAXUS NIR to the Platinum ION systems, the PES clinical trial program 
established safety and efficacy for the treatment of coronary artery lesions. Boston Scientific 
has also developed a drug-eluting stent with a biodegradable polymer, the JACTAX™ PES 
further discussed in section 8. In addition, the XIENCE V stent is also distributed as the 
PROMUS everolimus-eluting stent (EES) by Boston Scientific noted in Section 5.  
4. ENDEAVOR
®
 and RESOLUTE™ 
The Endeavor zotarolimus-eluting stent system (ZES) is the first DES manufactured by 
Medtronic, Inc., Santa Rosa, CA. The stent received FDA approval for commercialization in 
the U.S in February, 2008. The Endeavor DES utilizes the Driver BMS cobalt alloy stent and 
a phosphorylcholine lipophilic (PC) polymer coating outside of the stent for delivery of 
zotarolimus, which is an anti-proliferative drug eluted within 14 days and faster than the 
first generation DES. Another DES that utilizes zotarolimus was the ZoMaxx stent system 
manufactured by Abbott Vascular and became commercially available outside of the U.S. 
Zotarolimus is a highly lipophilic anti-proliferative drug that rapidly is dissolved and has 
been found to inhibit neointimal hyperplasia (Garcia-Touchard et al., 2006). The thin strut 
design (91µm) with the added benefit of rapid drug elution allows for rapid 
endothelialization, reduced inflammation and the promotion of healing.  
The Endeavor ZES was first studied in the Endeavor I single-arm, multicenter clinical trial 
and enrolled 100 patients with de novo coronary lesions measuring ≤ 15 mm in length in 
vessels with diameter sizes between 3.0-3.5 mm. The primary efficacy endpoint was in-stent 
late loss at 4 months and was 0.33 ± 0.36 mm and the primary safety endpoint was MACE at 
30 days and was 1.0% for the Endeavor ZES (Meredith et al., 2005). The Endeavor II clinical 
trial enrolled 1,197 patients and was a randomized multicenter trial comparing Endeavor 
ZES to the Driver BMS for treatment of single de novo lesion measuring > 14 mm and ≤ 27 
mm in vessel diameters between 2.25 – 3.5 mm. The primary endpoint was TVF at 9 months 
and the Endeavor arm (7.9%) demonstrated non-inferiority to the Driver BMS arm (15.1%) at 
9 months (p = 0.0001) (Fajadet et al., 2006). The Endeavor II clinical trial was extended as a 
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continued access trial (Endeavor II CA) and enrolled 296 additional patients in a single arm 
allowing single lesion treatment < 20 mm in vessel sizes 2.25 – 3.5 mm.  
The Endeavor III randomized multi-center trial enrolled 436 patients (3:1) comparing the 
Endeavor ZES to Cypher SES for single de novo lesion treatment measuring > 14 mm and ≤ 
27 mm in vessel diameters between 2.25 – 3.5 mm. The primary endpoint was in-segment 
late loss at 8 months and the Endeavor arm demonstrated numerically higher late loss (0.34 
± 0.44 mm) compared to the Cypher SES arm (0.13 ± 0.32) (Kandzari et al., 2006). Endeavor 
IV was the pivotal randomized clinical trial that enrolled 1,548 patients with a single de 
novo lesion measuring ≤ 27 mm in vessels measuring 2.5 mm-3.5 mm, thus restricting the 
small vessel sizes that had previously been evaluated in Endeavor I, II, and III. The trial had 
a clinical composite endpoint of target vessel failure (TVF; defined as cardiovascular death, 
MI, and target vessel revascularization) at 9 months and also included angiographic and 
IVUS endpoints. The primary endpoint was met and the Endeavor stent demonstrated non-
inferiority compared to the TAXUS Express PES at 9 months respectively, (6.6% versus 7.1%, 
p < 0.001), (Leon et al., 2010). Based on the results from the Endeavor II, III, and IV, it was 
evident that the Endeavor stent outperformed the Driver BMS in terms of reducing TLR, but 
the same outcome was not observed when compared to the current gold standard first 
generation stents (CYPHER and TAXUS). In the Endeavor III trial, the Endeavor arm had 
numerically higher late loss and TLR rates compared to the CYPHER arm, respectively 
(6.3% versus 3.5%) (Maeng et al., 2010). In the Endeavor IV trial, the Endeavor arm also had 
numerically higher TLR rates compared to the TAXUS arm through the 3 year follow-up, 
respectively (6.5% versus 6.0%) not showing improved efficacy over the first generation 
DES, which was expected with a next generation DES (Leon et al., 2009). Subsequently, a 
new DES, known as the RESOLUTE™ ZES was developed by Medtronic to improve upon 
the Endeavor stent (Maeng et al., 2010). 
The RESOLUTE ZES is the newest generation of DES developed by Medtronic currently 
under evaluation in randomized and all-comer trials that will be seeking FDA approval for 
commercialization in the U.S. in April, 2011 and has already received C.E. Mark status for 
outside of the U.S. in 2007. The RESOLUTE ZES utilizes the same stent as in DRIVER and 
ENDEAVOR and zotarolimus, but uses the BioLinx polymer outside coating for extended 
release of zotarolimus (Leon, 2011). The RESOLUTE first-in-man trial was a single-arm 
multicenter trial that enrolled 139 patients and evaluated in-stent late loss compared to the 
ENDEAVOR ZES matched cohort from Endeavor II. The late loss was reduced by 0.39 mm 
(p < 0.001) with the RESOLUTE stent and the TLR rate was 1.0% at 1 year, suggesting that 
delayed elution through the RESOLUTE stent design may translate to improved safety and 
efficacy (Meredith et al., 2009).  
The RESOLUTE All-Comers (RAC) trial was the first trial to compare RESOLUTE ZES to the 
next generation XIENCE V everolimus-eluting stent (EES) manufactured by Abbott Vascular 
(refer to section 5). The RAC trial is a randomized, open-label, multicenter investigation 
comparing 2,292 patients randomized 1:1 to RESOLUTE ZES or XIENCE V EES with a 
primary endpoint of target lesions failure (TLF; defined as cardiac death, target vessel MI, 
and target lesion revascularization)  at 1 year. The RESOLUTE ZES was found to be non-
inferior to the XIENCE V EES at 1 year. The RESOLUTE ZES arm TLF rate at 1 year was 
8.2% and the XIENCE V EES rate was 8.3% (p = non-inferiority) (Meredith, 2011). The trial 
evaluated notably more complex patient and lesion types than in the previous ENDEAVOR 
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or RESOLUTE trials where inclusion and exclusion criteria restricted more challenging 
cases. Clinical outcomes remained comparable overall through two years between treatment 
arms for death, MI, TLR, and ST events (Meredith, 2011).  
 
Trial Design 
Sample 
size 
Primary 
endpoint 
ZES 
treatment 
arm 
Comparator 
arm 
P value 
Endeavor I 
 
Single-arm, 
multicenter 100 
MACE at 
30 days; 
in-stent 
LL at 120 
days 
MACE 1%; 
in-stent LL 
0.33 ± 0.36 
mm 
Not 
applicable 
Not 
applicable 
Endeavor II 
 
Randomized, 
multicenter 
1,197 
TVF at 9 
months 
7.9% Driver 15.1% P = 0.0001 
Endeavor 
III 
Randomized, 
multicenter 
436 
In-
segment 
late loss at 
8 months 
0.34 ± 0.44 
mm 
 
CYPHER 
0.13 ± 0.32 
mm 
 
P < 0.001 
Endeavor 
IV 
 
Randomized, 
multicenter 
1,548 
TVF at 9 
months 
6.6% TAXUS 7.1% P < 0.001 
RESOLUTE 
Single-arm, 
multicenter, 
feasibility 
139 
In-stent 
late loss at 
9 months 
0.22 ± 0.27 
mm 
ENDEAVOR 
II (matched 
cohort) 0.62 
± 0.46 mm 
P < 0.001 
RESOLUTE 
All-Comers 
(RAC) 
 
Randomized, 
multicenter 
2,292 
TLF at 1 
year 
8.2% 
XIENCE V 
8.3% 
P < 0.001 
RESOLUTE 
U.S. 
 
Single-arm, 
multicenter 
1,402 
TLF at 1 
year 
3.7% 
ENDEAVOR 
(historical) 
6.5% 
P sup = 
0.002 
Table 4. Clinical trials evaluating the ENDEAVOR and RESOLUTE zotarolimus eluting 
stents 
A RESOLUTE U.S. trial is being conducted with 1402 patients in the RESOLUTE stent arm  
and is a single-arm, multicenter trial using Endeavor historical data as a comparator arm to 
evaluate the primary endpoint of target lesion failure (TLF; defined as cardiac death, target 
vessel MI, and target lesions revascularization) at 1 year. The RESOLUTE U.S. trial design 
allowed for 2.25 – 4.2 mm vessel diameter and lesion length ≤ 27 mm (Yeung et al., 2011). 
The trial evaluated for non-inferiority and superiority using a performance goal from the 
Endeavor program and was able to demonstrate both non-inferiority and superiority at 1 
year in terms of TLF. At 1 year, the RESOLUTE arm main cohort showed a 3.7% rate of TLF 
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compared to 6.5% from the Endeavor historical control arm (p non-infer. < 0.001 and p sup = 
0.002) (Leon, 2011). The numerically lower rates of TLF observed in the RESOLUTE arm 
compared to the historical Endeavor arm may be attributed to change in polymer (BioLinx) 
with subsequent extended release of zotarolimus. The RESOLUTE clinical trial program 
continues to follow patient outcomes for long-term follow-up and has also multiple trials 
currently underway OUS, such as the RESOLUTE International, the RESOLUTE Japan, 
RESOLUTE ASIA, and RESOLUTE CHINA. 
5. XIENCE V
®
 and XIENCE PRIME™ 
The XIENCE V everolimus-eluting stent (EES) was approved by the FDA on July 2, 2008 and 
is manufactured by Abbott Vascular. The XIENCE V stent/scaffold is the MULTILINK 
VISION bare metal stent and it is the thinnest strut platform of the DES approved for 
commercialization in the US to date. Compared to CYPHER (140 µm), TAXUS EXPRESS 
(132 µm), TAXUS Liberté (97 µm), and ENDEAVOR (91 µm), the XIENCE V (81 µm) strut 
remains the thinnest for first and second generation DES in the USA and is comparable to 
the Platinum Chromium Element stent (81 µm) (Smits, TCT 2009). XIENCE V uses an acrylic 
polymer primer coating outside of the stent, referred to as PBMA [poly (n-
butylmethacrylate)], covered by a fluorinated copolymer coating made of two monomeric 
compounds (vinylidene fluoride and hexafluoropropylene). XIENCE V was engineered to 
elute everolimus from a thin (7.8 micron), non adhesive, durable, biocompatible, and 
fluorinated copolymer (Bezenek et al., 2011). Everolimus is an anti-proliferative drug with 
anti-inflammatory properties that arrests the cell in the G1 phase. The XIENCE V EES 
clinical trial program has established a robust body of data. The SPIRIT FIRST study was a 
first-in-man, multi-center, randomized, controlled trial conducted in Europe to assess the 
feasibility and performance of the XIENCE V in the treatment of subjects with a single 
de novo native coronary artery lesion compared to the metallic, uncoated MULTI LINK 
VISION RX Coronary Stent System (VISION RX CSS). SPIRIT FIRST enrolled approximately 
60 patients with reference vessel size of 3 mm and a single lesion length ≤ 12 mm. The 
primary endpoint was in-stent late loss at 6 months and XIENCE V demonstrated 
superiority to the MULTI-LINK VISION BMS arm by meeting the primary endpoint with 
0.10 ± 0.23 mm late loss compared to the BMS arm late loss of 0.85 ± 0.36 mm (superiority 
P value < 0.0001). The trial was designed with a major secondary endpoint of % volume 
obstruction (%VO) and the XIENCE V arm demonstrated a 72% reduction in %VO 
compared to the BMS arm, respectively (8.0% versus 21.0%, p < 0.001). The trial has 
completed 5 year follow-up and notably, there was no stent thrombosis event reported in 
either arm in the SPIRIT FIRST study. Safety and efficacy results evident in the SPIRIT 
FIRST trial led to the SPIRIT II trial.  
The SPIRIT II trial was a multi-center randomized trial (3:1) designed to continue assessing 
the safety and performance of the XIENCE V in the treatment of patients with a maximum 
of two de novo native coronary artery lesions each in a different epicardial vessel, compared 
to TAXUS. The SPIRIT II clinical study arm allowed the treatment of de novo lesions ≤ 28 
mm in length in coronary arteries with a reference vessel diameter (RVD) ≥ 2.5 mm to ≤ 4.25 
mm. Three hundred (300) patients were enrolled in the study; 223 patients were treated with 
XIENCE V, 59 patients were treated with TAXUS EXPRESS, and 17 patients received 
TAXUS Liberté. The primary endpoint was in-stent late loss at 6 months and was designed 
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with angiographic and IVUS endpoints. The trial was powered for a major secondary endpoint 
of in-segment late loss as well. XIENCE V® demonstrated non-inferiority to the TAXUS® arm 
in terms of the primary endpoint of in-stent late loss. The XIENCE V arm was 0.11 ± 0.27 mm 
compared to 0.36 ± 0.39 mm in the TAXUS arm (p < 0.0001). The primary endpoint 
demonstrated that XIENCE V® was statistically superior to the TAXUS® (superiority P value < 
0.0001). The in-segment late loss results favored the XIENCE V arm compared to the TAXUS 
arm with a 53% reduction observed at 6 months. The clinical follow-up through 5 years 
supported the safety and efficacy of the XIENCE V EES and no late catch-up was observed. 
The SPIRIT III pivotal clinical trial was designed to demonstrate the non-inferiority of 
XIENCE V to TAXUS. Conducted in the United States (US) and Japan, the SPIRIT III clinical 
trial was composed of a randomized clinical trial in the US (RCT) and a non-randomized 
arm (4.0 mm arm) and one non-randomized arm in Japan. The SPIRIT III RCT was designed 
as a randomized (2:1), multi-center non-inferiority evaluation of the XIENCE V stent 
compared to the TAXUS stent and enrolled a total of 1002 patients (669 patients in XIENCE 
V arm and 333 patients in the TAXUS arm). Treatment of up to two de novo lesions ≤ 28 mm 
in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 3.75 mm was permitted. The 
trial design had a primary efficacy endpoint of in-segment late loss at 8 months and also a co-
primary endpoint of TVF at 9 months. In the SPIRIT III RCT arm, XIENCE V was found to be 
statistically non-inferior to TAXUS (Stone, 2010). The primary endpoint of in-segment LL at 8 
months results for the XIENCE V arm was 0.14 ± 41 mm and for the TAXUS arm was 0.28 mm 
± 48 mm (p non-inferior < 0.0001). Additionally, since non-inferiority was demonstrated, a 
superiority analysis of the primary endpoint was performed using a two-sided t-test with 
alpha = 0.05. The analysis showed the superiority of XIENCE V to the TAXUS arm in terms of 
the primary endpoint of in-segment LL at 8 months (p superior = 0.0037). The major secondary 
endpoint of TVF was also met with the XIENCE V arm demonstrating numerically lower rates 
(7.6%) compared to the TAXUS arm (9.7%) at 9 months (p non-inferior < 0.0001).  
As part of the SPIRIT III clinical trial design, the non-randomized 4.0 mm arm was 
compared to the TAXUS patients of the RCT arm. The SPIRIT III 4.0 mm arm trial 
demonstrated consistent results with the SPIRIT III RCT arm. The SPIRIT III 4.0 mm non-
randomized arm demonstrated non-inferiority of XIENCE V 4.0 mm arm compared to the 
TAXUS RCT arm in terms of the primary endpoint of in-segment LL at 8 months (p non-
inferior < 0.0001). In-segment LL at 8 months was 0.17 ± 0.38 mm for the XIENCE V 4.0 mm 
arm and 0.28 ± 0.48 mm for the TAXUS RCT arm. The third cohort of the SPIRIT III trial that 
actively enrolled patients was the SPIRIT III Japan single-arm trial. In the SPIRIT III Japan 
arm, the XIENCE V arm was also found to be statistically non-inferior to TAXUS RCT arm. 
The primary endpoint of the trial was met with in-segment LL results of 0.15 ± 0.34 mm for 
the XIENCE V Japan arm and 0.28 ± 0.48 mm for the TAXUS RCT arm at 8 months. The 
XIENCE V Japan arm also demonstrated non-inferiority to the TAXUS RCT arm for in-
segment LL at 8 months (p non-inferior < 0.0001). No stent thrombosis occurred through 
two-year follow-up in the XIENCE V Japan arm. Clinical results of treatment with XIENCE 
V in the SPIRIT III trial supported the safety and efficacy of XIENCE V and since approval in 
the U.S., has demonstrated long-term follow-up with 5 year results available this year at 
TCT 2011. In order to expand XIENCE V use to more complex patients, the SPIRIT IV 
clinical trial was designed to allow for multiple lesions to be treated beyond what was 
previously evaluated in earlier randomized trials for comparing DES. 
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The SPIRIT IV clinical trial was a randomized (2:1) multi-center evaluation of the XIENCE V 
EES compared to the TAXUS PES in the treatment of up to three de novo lesions ≤ 28 mm in 
length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 3.75 mm. There were 3,687 
patients enrolled and they were stratified based on diabetes mellitus status (diabetic vs. non-
diabetic) and lesion characteristics (complex vs. non-complex). Complex lesion characteristics 
included triple vessel treatment, or dual lesions per vessel treatment, or lesions involving 
RCA-aorto-ostial locations, or bifurcations lesions. The primary endpoint was TLF at 1 year 
and two major secondary endpoints were also evaluated; TLR and the composite of target 
vessel MI and cardiac death at 1 year. In the SPIRIT IV clinical trial, XIENCE V demonstrated 
non-inferiority to TAXUS in terms of the primary endpoint of TLF respectively, (4.2% 
compared to 6.8%, p non-inferior < 0.0001). Since non-inferiority was demonstrated, the pre-
specified superiority test of the primary endpoint was performed. Superiority of XIENCE V 
over TAXUS for the primary endpoint (p superior = 0.0012) was also met at 1 year.  
Additional pre-specified hypothesis tests for non-inferiority and superiority were performed 
for the major secondary endpoints of TLR and cardiac death or target vessel MI at 1 year. The 
XIENCE V arm demonstrated non-inferiority to the TAXUS arm in terms of TLR rates at 1 
year, respectively (2.5% and 4.6%, p non-inferior < 0.0001). For cardiac death or target vessel 
MI, the XIENCE V arm also demonstrated non-inferiority to the TAXUS arm respectively, 
(2.2% compared to 3.2%, p non-inferior < 0.0001). Moreover, the XIENCE V arm also 
demonstrated superiority (p superior = 0.0012) over the TAXUS arm for TLR, but did not meet 
superiority (p superior = 0.0899) for cardiac death or target vessel MI at 1 year. The SPIRIT IV 
trial showed numerically low ARC (definite/probable) ST rates through the two-year follow-
up in the XIENCE V arm (0.42%) compared to the TAXUS arm (1.23%), consistent with earlier 
SPIRIT trials, but in a more complex patient population. A similar finding was observed in the 
all-comers, single arm post-marketing trial, the XIENCE V USA trial discussed here below. 
The XIENCE V USA post-marketing safety and surveillance trial was designed as a single-
arm, multicenter, open-label trial that enrolled 5,054 patients in the U.S following FDA 
approval of the XIENCE V EES in 2008. As part of the requirements for FDA approval, the 
XIENCE V USA evaluated the real-world usage of the XIENCE V EES in clinical practice 
and monitor safety outcomes. The primary endpoint is the composite of definite/probable 
ST rates as defined by the Academic Research Consortium (ARC) definitions and also has a 
co-primary endpoint of cardiac death and MI at 1 year and will follow patients through 5 
year follow-up. As the trial is a post-approval study, the restrictions of inclusion and 
exclusion criteria do not limit the enrollment and thus provide a perspective of outcomes in 
patients that have not been evaluated in pivotal RCTs, such as AMI, in-stent restenosis, or 
chronic total occlusions. Despite having more complex subgroups, the XIENCE V patients 
have demonstrated consistent results at 1 year with ST rates comparable to the SPIRIT III 
pivotal trial, which only allowed for a single lesion per vessel treatment of less than 28 mm. 
At 1 year, the XIENCE V USA ST rate was 0.8% and the cardiac death and MI rate was 6.3% 
(Hermiller, 2010).  
More recently, the XIENCE V nano EES was approved by the FDA in May 2011 for the 
treatment of small vessels. The XIENCE V nano EES was approved as a line extension to the 
existing XIENCE V EES based on the results of the SPIRIT Small Vessel (SV) single-arm, 
multicenter clinical trial. The purpose of the SPIRIT SV trial was to evaluate the safety and 
efficacy of the 2.25 mm XIENCE V EES in improving coronary luminal diameter in subjects 
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with symptomatic heart disease due to a maximum of two de novo native coronary artery 
lesions measuring ≤ 28 mm in small vessels (≥ 2.25 mm to < 2.50 mm), each in a different 
epicardial vessel. The study was designed to enroll up to 150 patients with the first 60 
patients enrolled in the angiographic cohort requiring angiographic follow-up at 8 months. 
The primary endpoint was TLF at 1 year and was required to meet a pre-specified 
performance goal of 20.4% at 1 year. The study was designed to enroll up to 150 patients 
with the first 60 patients enrolled in an angiographic cohort requiring angiographic follow-
up at 8 months. The 1-year TLF rate was 8.1%and therefore met the performance goal of 
20.4% and met the primary endpoint (p<0.0001). The mean in-segment late loss at 8 months 
was 0.16 ± 0.41 mm and the mean in-stent late loss was 0.20 ± 0.40 mm, both slightly higher 
compared to the in-segment (0.14 ± 0.41 mm) and in-stent late loss (0.16 ± 0.41 mm) reported 
in the XIENCE V arm of SPIRIT III RCT, yet lower than the in-segment and in-stent late loss 
for SPIRIT III RCT TAXUS arm, respectively (0.28 ± 0.48 mm and 0.30 ± 0.53 mm).  
5.1 XIENCE PRIME™ 
As observed in the XIENCE V USA post-marketing single-arm trial, the complexity of 
patients and lesions being treated with DES is requiring more specialized treatments and 
challenging cases in the catheterization lab. In order to address this market need, the 
XIENCE PRIME and XIENCE PRIME Long Lesion (LL) EES were developed from the 
framework of the XIENCE V EES with modifications to further enhance deliverability, 
flexibility, and stent retention. The XIENCE PRIME utilizes an improved cobalt chromium 
alloy stent, but the same polymer composition of the poly n-butyl methacrylate (PBMA) 
primer coating, drug reservoir layer of poly vinylidene fluoride co-hexafluoropropylene 
(PVDF-HFP), and the same everolimus/polymer weight to weight combination ratio and 
thickness. XIENCE PRIME also uses the same anti-proliferative drug (everolimus) and has 
the same drug density (100µg/cm2) as the original XIENCE V EES design. The strut 
thickness remains one of the thinnest available to date at 81µm. Both the XIENCE V and the 
XEINCE PRIME were built upon the MULTI-LINK BMS design, but the XIENCE PRIME has 
the added features of the MULTI-LINK 8™ BMS design, where a  link has been made taller 
and the cell has been lengthened. The delivery system also underwent important 
modifications that include a smooth rounded tip, designed to enhance tracking, and 
deliverability, while the shorter balloon taper aims to reduce stent injury. 
The objective of the SPIRIT PRIME clinical trial is to evaluate the safety and effectiveness of 
the XIENCE PRIME™ and XIENCE PRIME LL™ EES in improving coronary luminal 
diameter in subjects with symptomatic heart disease. The XIENCE PRIME and XIENCE 
PRIME LL EES enrolled patients with symptomatic heart disease due to de novo native 
coronary artery lesions (lesion length ≤ 32 mm) with vessel diameters measuring ≥ 2.25 mm 
and ≤ 4.25 mm. The study was designed as a single-arm, open-label, multi-center non-
randomized clinical trial using the core size XIENCE PRIME and XIENCE PRIME LL. 
Approximately 500 subjects were enrolled; 400 in the Core Size Registry (CSR) and 100 in 
the Long Lesion Registry (LLR), which included stent lengths of 33 and 38 mm. The primary 
endpoint of TLF at one year was required to meet pre-specified (per protocol) performance 
goals (PG); the CSR PG was 9.2% and the PG for the LLR was 19.2%. The XIENCE PRIME 
met the primary endpoint for both the CSR and the LLR in terms of TLF rates at 1 year with 
6.5% for the CSR (p = 0.0038) and 12.5% for the LLR (p = 12.5%) as per ARC MI definition. 
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Thus meeting the primary endpoint, the XIENCE PRIME Pre-Market Approval (PMA) 
packet has been submitted for FDA approval in April, 2011 by Abbott Vascular and is 
pending approval for commercialization in the U.S. XIENCE PRIME has already received 
C.E. Mark for commercialization in Europe since June, 2009. Long-term follow-up continues 
for XIENCE PRIME, Small Vessel, SPIRIT IV, and XIENCE V USA to further support the 
robust data supporting the safety and efficacy profile.  
 
Trial Design 
Sample 
size 
Primary 
endpoint 
EES 
treatment 
arm 
Comparator 
arm 
P value 
SPIRIT 
FIRST 
 
Randomized, 
multicenter 
60 
In-stent 
late-loss at 
6 months 
0.10 ± 0.23 
mm 
BMS 0.85 
±0.36 mm 
P < 0.001 
SPIRIT II 
 
Randomized, 
multicenter 
300 
In-stent 
late-loss at 
6 months 
0.11 ± 0.27 
mm 
TAXUS 0.36 
± 0.39 mm 
P < 0.0001 
 
SPIRIT III 
 
 
Randomized, 
multicenter 
1,002 
In-segment 
late loss at 8 
months 
0.14 ± 0.41 
mm 
TAXUS 0.28 
± 0.48 mm 
P superiority 
= 0.004 
SPIRIT IV 
 
Randomized, 
multicenter 
3,687 
TLF at 1 
year 
4.2% 
TAXUS 
6.8% 
P superiority 
= 0.001 
XIENCE 
V USA 
 
Single-arm, 
multicenter, 
open label 
5,054 
Composite 
of Stent 
Thrombosis
0.8% 
Not 
applicable 
Not 
applicable 
SPIRIT 
Small 
Vessel 
(SV) 
 
Single-arm, 
multicenter, 
open label 
144 
TLF at 1 
year 
8.1% PG* 20.4% P < 0.0001 
SPIRIT 
PRIME 
 
Single-arm, 
multicenter, 
open label 
419 CSR◊ 
arm 
 
110 LLR▲ 
arm 
TLF at 1 
year 
CSR 6.5% 
LLR 12.5%
PG 9.2% 
PG19.2% 
P = 0.034 
P = 0.048 
Of note, the XIENCE V stent is also distributed as the PROMUS EES by Boston Scientific.  
* PG = performance goal; ◊CSR = Core Sample Registry; ▲LLR = Long Lesion Registry 
Table 5. Clinical Trials evaluating the XIENCE V and the XIENCE PRIME everolimus-
eluting stents 
6. Longterm trial results 
Key trials discussed above have already completed or are reaching the final year of follow-
up. The question of improved clinical outcomes with DES over BMS has been established 
with long-term safety profiles available from all of the leading manufacturers. The question 
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of which DES has sustained the most improved clinical outcomes remains debatable 
depending on the patient needs and ability to adhere to the indicated dual antiplatelet 
therapy recommended of aspirin and clopidogrel, as per the DES PCI recommendations 
(King et al., 2007). The long-term follow-up available from key DES trials is presented in 
Table 6. 
 
Trial 
 
Treatment 
Arms 
Follow-up
Year 
Cardiac 
death 
% 
MI % TLR % TVR % 
Stent 
Thrombosis 
(ARC 
def/prob %) 
RAVEL 
(Morice et al., 
2007) 
 
CYPHER SES  
 
5 
12.1 8.9 10.3 2.7 3.3 
BMS 
 
7.1 6.9 26.0 2.6 6.8 
(all 
death)
 P<0.001  (all ARC) 
SIRIUS 
 
CYPHER SES  
5 
4.1 6.2 9.4 16.5 1.2 
BMS 3.6 6.5 24.2 30.5 1.8 
  P<0.001 P<0.001  
TAXUS IV 
(Ellis et al., 
2009a) 
TAXUS 
Express PES
5 
4.4 7.2 9.1 16.9 2.2 
BMS 
 
4.5 7.4 20.5 27.4 2.1 
  P<0.0001 P<0.0001  
TAXUS V 
(Ellis et al., 
2009b) 
TAXUS 
Express PES
5 
3.8 8.4 16.3 
Not 
available
1.9 
BMS 
 
1.6 5.4 22.3 0.7 
P=0.04  P=0.005  
ENDEAVOR 
III 
(Kandzari et 
al., 2011) 
ENDEAVOR 
ZES 
 
CYPHER SES
5 
0.3% 
 
2.8% 
1.0% 
 
4.6% 
P=0.03
8.1% 
 
6.5% 
16.9% 
 
13.0% 
0.7% 
 
0.9% 
ENDEAVOR 
IV 
(Leon et al., 
2010) 
ENDEAVOR 
ZES 
 
 
3 
1.7 2.1 6.5 9.9 1.1 
TAXUS 
Express PES
2.4 4.9 6.1 10.9 1.7 
 P=0.005    
SPIRIT III 
(Stone, 2010b) 
XIENCE V 
4 
2.6 4.4 7.6 13.4 1.4 
TAXUS 
Express 
2.6 6.6 10.3 16.1 1.6 
 
SPIRIT IV 
(Stone, 2010a) 
 
XIENCE V 
2 
0.9% 2.5%  
4.5% 
 
 
3.9% 
 
 
0.42% 
 
TAXUS 
Express 
 
1.3% 
 
3.9% 
(P=0.02)
 
6.9% 
(P=0.004)
 
4.3%  
1.23% 
(P=0.008) 
(Available significant P values (≤ 0.05) are included above). 
Table 6. Long-term Clinical Outcomes Currently Available 
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7. Current challenges 
A challenge that remains when comparing DES head to head across trials is the 
inconsistency between definitions. In order to address this challenge, the Academic 
Research Consortium (ARC) developed standardized definitions for clinical trial endpoints 
(Cutlip et al., 2007). The ARC definitions have now become the gold standard for clinical 
trial endpoints and definitions of clinical events, such as cardiac deaths, MI, and ST. In 
addition, clinical events may be retrospectively adjudicated by Clinical Events Committees 
(CEC) using the ARC definitions for post ad-hoc analysis of events not initially evaluated 
using the ARC definitions. The ARC definitions particularly met the need of unifying the ST 
definition that differed across stent manufacturers and clinical trials. One of the main 
concerns with using DES initially was the additional risk of ST possibly due to delayed 
healing, inflammation or incompatibility between polymer and the vessel (Lagerqvist et al., 
2007; Moreno et al., 2005). First generation DES have observed higher rates of very late ST 
compared to BMS (Camenzind et al., 2007; Daemen et al., 2007; Farb and Boam, 2007; 
Pfisterer et al., 2006). Several DES specific characteristics may contribute to the development 
of ST, such as choice of drug, polymer, and strut thickness. Other patient specific 
characteristics may contribute, such as patient co-morbidities (diabetes, renal failure and 
acute MI) and lesion characteristics. Compliance to DAPT and platelet responsiveness also 
plays a role in ST rates observed in DES (Bezenek et al., 2011). Procedural factors related to 
smaller luminal dimensions, such as stent under-expansion or malapposition are risk factors 
for ST, in addition to stent length, multi-stenting, persistent slow flow, positive remodeling, 
dissections, geographic miss, residual stenosis, and late stent malapposition which have all 
been related to ST (Bezenek et al., 2011). Furthermore, well established criteria for the 
duration and dose with existing antiplatelet medication, as well as the role of newly 
emerging antiplatelet medications does not exist currently. Although the ARC definitions 
did provide a common reference for ST definitions concerning timing and severity, the 
appropriate standardized dose of DAPT remains in question with DES use. Despite these 
challenges however, few DES have emerged as demonstrating a consistent numerically low 
rate of ST across clinical trials. The XIENCE V and XIENCE PRIME DES remain two of the 
DES with the lowest ST event profile across RCT, single-arm, and all-comer trials, despite 
reduced DAPT compliance observed at 2 years in the COMPARE all-comers trial; the 
combination of stent design, thin struts, bio-compatible polymer coating technologies, and 
drug may contribute to numerically low ST rates consistently observed (Bezenek et al., 2011). 
8. Additional stent technology 
In order to address the concern for potential increased risk of late/very late ST with DES, 
several manufacturers developed biodegradable polymers and bioabsorbable scaffolds that 
degrade over time. Durable polymers may be associated with increased complications and 
clinical events and new developments in DES are integrating dissolvable polymers and 
scaffolds to eliminate this potential problem. Abbott Vascular currently has the ABSORB™ 
clinical trial program that is evaluating the everolimus-eluting bioresorbable vascular 
scaffold (BVS) in global clinical trials. The ABSORB BVS clinical trial program is evaluating 
the safety and efficacy of fully bioabsorbable scaffold that is comprised of a poly-L-lactic 
acid backbone and has a poly-D, L-lactic acid coating that modulates the release of 
everolimus. The ABSORB international clinical trials that have enrolled patients thus far 
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include ABSORB Cohorts A and Cohort B and ABSORB EXTEND. The ABSORB Cohort A 
trial enrolled 30 patients and was designed to evaluate the safety and performance of 
ABSORB BVS in single de novo lesions. The 4-year clinical event rates remain numerically 
low with no events of scaffold thrombosis occurring (Chevalier, 2011). The ABSORB Cohort 
B trial enrolled 101 patients and allowed up to two de novo lesions to be treated. Current 12- 
month results for Cohort B were presented at the American College of Cardiology (ACC) 
and reported that no scaffold thrombosis have occurred either by ARC or per protocol 
definitions as well (Serruys, 2011). The ABSORB EXTEND trial plans to enroll up to 1000 
patients at up to 100 international sites and will continue to assess the safety and 
performance of ABSORB BVS in up to two de novo lesions, allowing for the evaluation of 
longer lesions and overlapping scaffolds.  
As mentioned earlier, the NEVO stent was a new technology in development by Cordis 
Corporation, Johnson and Johnson, and used polylactic-co-glycolic acid (PGLA) loaded in 
reservoirs drilled through the struts of a cobalt chromium stent and has subsequently been 
removed from further development (Belardi, 2011; Otake et al., 2011b). The JACTAX™ 
biodegradable stent system is developed by Boston Scientific and uses D-lactic polylactic 
acid (DLPLA) mounted on the TAXUS Liberté stent whose outside coating elutes paclitaxel 
(Grube et al., 2010; Shand, 2010) . The Biolimus-A9 TM eluting BioMatrix™ stent system 
(Biosensors Interventional Technologies Pte Ltd, Singapore) incorporates a biodegradable 
polylactic acid (PLA) coated on the outside of the S-Stent stainless steel stent that scaffolds 
the artery (Abizaid et al., 2011; Shand, 2010). The Leaders trial was designed to compare the 
BioMatrix stent to the CYPHR stent and enrolled 1707 patients (randomized 1:1) with a 
composite clinical primary endpoint of cardiac death, MI, and clinically-indicated target 
vessel revascularization (Windecker et al., 2008). The primary endpoint was met and 
BioMatrix demonstrated non-inferiority compared to CYPHER (9.2% versus 10.5%; P=0.003) 
and has sustained numerically low rats of very-late ARC-defined definite stent thrombosis 
through 3 years, respectively (0.2% versus 0.9%), (Windecker, 2011; Windecker et al., 2008). 
The CardioMind Sparrow is developed by CardioMind, Inc. and is a self-expandable nitinol 
stent with a PLA/PLGA copolymer biodegradable outside coating (Abizaid et al., 2011). The 
ELIXER-DES™ is under development by the Elixer Medical Group and has a cobalt-
chromium stent as the scaffold and uses polyester or polylactide based biodegradable 
polymer coating over the outside of the stent. Other technologies are moving toward 
polymer-free DES as well, such as the BioFreedom™ (Biosensors Inc.), the VESTAsync™ 
(MIV Therapeutics), and the Optima™ (CID S.r.I) with further specialized designs using 
biolimus A9, sirolimus, and tacrolimus, respectively (Abizaid et al., 2011). Lastly, 
endothelium progenitor cell (EPC) capture stents were developed (Genous™ manufactured 
by OrbusNeich, Florida, USA) coated with CD34 antibodies that were to bind to circulating 
EPCs. The EPC capture stents have yet to show clinical trials demonstrating safety and 
efficacy superior to DES and have not become mainstream treatment options to date (Garg 
et al., 2010). 
9. Conclusion 
In conclusion, DES has emerged as a treatment of choice for patients that are suitable 
candidates with no restrictions to physician recommended DAPT medication. The first and 
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next generation DES evaluated in the CYPHER, TAXUS, ENDEAVOR, and XIENCE V 
clinical programs significantly reduced restenosis compared to BMS and have demonstrated 
comparable safety outcomes. In order to address potential polymer induced inflammation 
or delayed healing related safety events in current FDA approved DES, new technologies 
using biodegradable polymers, polymer-free DES, and bioresorbable stent scaffolds have 
emerged to further enhance PCI options. Long-term clinical results have clearly supported 
the safety and efficacy of DES and more specialized DES designs and trials for specific 
patient and lesion unmet needs continue to be pursued. 
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